HH Biotechnology Holdings Company
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorpora… Read more
HH Biotechnology Holdings Company (HHBT) - Total Assets
Latest total assets as of September 2016: $42.75 Million USD
Based on the latest financial reports, HH Biotechnology Holdings Company (HHBT) holds total assets worth $42.75 Million USD as of September 2016.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HH Biotechnology Holdings Company - Total Assets Trend (2012–2015)
This chart illustrates how HH Biotechnology Holdings Company’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HH Biotechnology Holdings Company - Asset Composition Analysis
Current Asset Composition (December 2015)
HH Biotechnology Holdings Company's total assets of $42.75 Million consist of 23.1% current assets and 76.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.1% |
| Accounts Receivable | $911.05K | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $35.73 Million | 76.9% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2015)
This chart illustrates how HH Biotechnology Holdings Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HH Biotechnology Holdings Company's current assets represent 23.1% of total assets in 2015, an increase from 10.4% in 2012.
- Cash Position: Cash and equivalents constituted 21.1% of total assets in 2015, up from 10.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is property, plant & equipment at 76.9% of total assets.
HH Biotechnology Holdings Company Competitors by Total Assets
Key competitors of HH Biotechnology Holdings Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Aurora Eiendom A.S.
OL:AURA
|
Norway | Nkr9.08 Billion |
|
PT Multisarana Intan Eduka Tbk
JK:MSIE
|
Indonesia | Rp124.39 Billion |
|
Shenzhen SEG Co Ltd
SHE:000058
|
China | CN¥5.05 Billion |
|
Beijing Mainstreets Investment
SHE:000609
|
China | CN¥1.92 Billion |
|
5I5j Holding Group Co Ltd
SHE:000560
|
China | CN¥26.38 Billion |
|
DongGuan Winnerway Industrial Zone Ltd
SHE:000573
|
China | CN¥2.14 Billion |
|
Rongfeng Holding Group
SHE:000668
|
China | CN¥1.28 Billion |
|
Sanxiang Co Ltd
SHE:000863
|
China | CN¥5.88 Billion |
HH Biotechnology Holdings Company - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - HH Biotechnology Holdings Company generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, HH Biotechnology Holdings Company generates $5.33 in net profit.
HH Biotechnology Holdings Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 0.59 | 0.59 |
| Quick Ratio | 0.34 | 0.59 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.70 Million | $ -7.37 Million | $ -7.37 Million |
HH Biotechnology Holdings Company - Advanced Valuation Insights
This section examines the relationship between HH Biotechnology Holdings Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -13.9% |
| Total Assets | $46.46 Million |
| Market Capitalization | $270.33 USD |
Valuation Analysis
Below Book Valuation: The market values HH Biotechnology Holdings Company's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: HH Biotechnology Holdings Company's assets decreased by 13.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HH Biotechnology Holdings Company (2012–2015)
The table below shows the annual total assets of HH Biotechnology Holdings Company from 2012 to 2015.
| Year | Total Assets | Change |
|---|---|---|
| 2015-12-31 | $46.46 Million | -13.94% |
| 2014-12-31 | $53.98 Million | -9.35% |
| 2013-12-31 | $59.56 Million | +0.20% |
| 2012-12-31 | $59.43 Million | -- |